Gain Therapeutics announced that preclinical studies with two of its compounds, GT-02287 and GT-02329, showed they could reduce the alpha-synuclein aggregates that characterize Parkinson’s and increase glucocerebrosidase protein levels in cell models of Parkinson’s and Gaucher disease. GT-02287 and GT-02329 are known as STARs, which stands for structurally targeted…
Scientists from Northwestern University will use two grants — totaling $17.9 million — from the Aligning Science Across Parkinson’s (ASAP) initiative to study alterations in the brain that contribute to the development of Parkinson’s disease. Their research focuses on brain circuits, the specific populations of interconnected brain cells…
A team of scientists from the University of Florida (UF) will use a $1.1 million grant to further their work on the use of artificial intelligence- or AI-powered medical research for predicting and diagnosing Parkinson’s disease while maintaining patient privacy. This grant, from the National Institutes for Health (NIH),…
Fascinate Therapeutics has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KM-819 as a potential therapy for Parkinson’s disease, the company announced in a press release. Parkinson’s disease is characterized by the death and dysfunction…
A specific genetic variant, or mutation, that is associated with an increased risk of developing amyotrophic lateral sclerosis (ALS) may also raise a person’s risk of Parkinson’s disease, a study reported. Shared features of both these neurodegenerative disorders include causative processes and “genetic backgrounds,” the researchers noted, suggesting that a mutation affecting…
Jubilee BioTech has developed JUBIwatch, a new device intended to improve patients’ medication adherence — taking medicines at the right time with the right dose. Under development by the startup South Korean company for the past two years, JUBIwatch is a smart watch and medication management platform that uses microneedles…
A team of researchers at Caltech will be looking into the interactions between the brain and the gut in Parkinson’s, in the hope of uncovering how their interaction may affect the disease. Studies are noting abnormalities in the gastrointestinal environment of Parkinson’s patients, and a better understanding of “gut-brain connections”…
The launch of a Phase 2 trial into the safety and early efficacy of oral NE3107 in treating Parkinson’s disease patients with motor fluctuations while on levodopa was approved by the U.S. Food and Drug Administration (FDA), BioVie, the therapy’s developer, announced. BioVie plans to initiate patient enrollment for the trial,…
A neurological surgery professor from Weill Cornell Medicine and his team will use a three-year, $8.9 million research grant to investigate how abnormal protein clumps in the gut can spread to the brain and help drive the early stages of Parkinson’s disease. This grant, from the Aligning Science Across…
Altoida announced a three-year collaboration with a Greek university to investigate whether the company’s precision neurology medical device can aid in the early detection of Parkinson’s disease. The agreement between Altoida and scientists at the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), part of Ionian University in Corfu,…
Get regular updates to your inbox.